Home » Research & Development

Research & Development

What is AbIMP® Technology?
The development of selective chemical inhibitors of metalloproteinases belonging to the metzincin superfamily remains a significant technical challenge despite decades of research and development predominantly focused on the matrix metalloproteinases… Read more

The ADAMs Family of Sheddases-New Emerging Therapeutic Targets
The ADAMs gene family of cellular sheddases are exciting, new therapeutic targets and biomarkers emerging within several clinical arenas… Read more

ADAM15, A Novel Anti-angiogenic Target
ADAM15 is a “sheddase” known to promote pathological angiogenesis in models of ocular neovascular disease and whose expression correlates strongly with the progression of several aggressive adenocarcinomas… Read more

ADAM15 as an Emerging Cancer Target
In addition to its role in the vasculature, ADAM15 is also associated with the progression of several adenocarcinomas. Clinical studies have identified that ADAM15 expression is elevated in the aggressive forms of prostate and breast cancers correlating strongly with… Read more

The Need for New Anti-angiogenic Drugs
Angiogenesis is a term given to the growth of new blood vessels from pre-existing vasculature and is essential for organ development, growth and wound healing. However, angiogenesis is also associated with numerous pathologies most notably cancer progression… Read more

Unmet Clinical Needs in Anti-angiogenic Ocular Therapy
Anti-angiogenesis therapy has revolutionized patient care in the treatment of ocular neovascular diseases such as wet age related macular degeneration (wet AMD) and permeability disorders such as diabetic macular oedema (DMO) and retinal vein occlusion (RVO)… Read more

Unmet Clinical Needs in Anti-angiogenic Cancer Therapy
For the treatment of cancer, anti-angiogenic therapy includes various classes of drugs that target VEGF and its receptors and those that inhibit other targets which disrupt angiogenesis by an unknown mechanism. Anti-VEGFs are used either as single agents… Read more